Citation: Ch. Chesnut et Cj. Rosen, Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture, J BONE MIN, 16(12), 2001, pp. 2163-2172
Authors:
Looker, AC
Bauer, DC
Chesnut, CH
Gundberg, CM
Hochberg, MC
Klee, G
Kleerekoper, M
Watts, NB
Bell, NH
Citation: Ac. Looker et al., Clinical use of biochemical markers of bone remodeling: Current status andfuture directions, OSTEOPOR IN, 11(6), 2000, pp. 467-480
Citation: He. Gruber et al., Osteoblast numbers after calcitonin therapy: A retrospective study of paired biopsies obtained during long-term calcitonin therapy in postmenopausal osteoporosis, CALCIF TIS, 66(1), 2000, pp. 29-34
Authors:
Chesnut, CH
Silverman, S
Andriano, K
Genant, H
Gimona, A
Harris, S
Kiel, D
LeBoff, M
Maricic, M
Miller, P
Moniz, C
Peacock, M
Richardson, P
Watts, N
Baylink, D
Citation: Ch. Chesnut et al., A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study, AM J MED, 109(4), 2000, pp. 267-276
Authors:
Harris, ST
Watts, NB
Genant, HK
McKeever, CD
Hangartner, T
Keller, M
Chesnut, CH
Brown, J
Eriksen, EF
Hoseyni, MS
Axelrod, DW
Miller, PD
Citation: St. Harris et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial, J AM MED A, 282(14), 1999, pp. 1344-1352